IQVIA Holdings Inc. with ticker code (IQV) have now 18 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $286.00 and $200.00 calculating the average target price we see $241.39. Now with the previous closing price of $215.39 and the analysts are correct then there would likely be a percentage uptick in value of 12.1%. The 50 day moving average now sits at $215.82 and the 200 day moving average is $208.48. The total market capitalization for the company now stands at 39.74B. The current share price for the company is: $217.75 USD
The potential market cap would be $44,536,366,033 based on the market consensus.
The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of 36.47, revenue per share of $80.44 and a 4.9% return on assets.
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.
